SHERIDAN, WYOMING - April 03, 2026 - Perimeter Medical Imaging AI has secured FDA premarket approval (PMA) for Claire, making it the first AI-enabled imaging device cleared in the United States for intraoperative breast cancer margin assessment during lumpectomy procedures. Claire, previously marketed as the Perimeter OCT B-Series with ImgAssist AI 2.0, holds FDA Breakthrough Device designation and targets an estimated 300,000 annual U.S. breast-conserving surgeries where residual disease forces re-operations in roughly one in five cases. The approval positions Perimeter to launch a nationwide commercial rollout in the weeks following clearance, converting a clinical trial asset into a revenue-generating platform with expansion potential across additional cancer indications.
What Claire does intraoperatively
Claire combines wide-field optical coherence tomography (OCT) with a proprietary AI engine trained on over two million proprietary breast tissue images to deliver real-time, three-dimensional margin evaluation of excised lumpectomy specimens. The system achieves ten times higher resolution than standard intraoperative X-ray and ultrasound at a two-millimeter imaging depth - the clinically relevant margin width for breast cancer assessment. Surgeons receive AI-flagged areas of concern before closing the operative field, enabling same-session tissue removal decisions rather than waiting up to ten days for standard pathology results.
Under current practice, surgeons rely on physical examination and, in limited cases, intraoperative pathology before sending specimens for final histopathological review. Claire is designed to adjunct - not replace - that workflow by identifying suspicious focal areas in real time. The device is cleared for use alongside physician image interpretation and must not substitute for standard tissue histopathology.
Pivotal trial results and clinical validation
The pivotal trial supporting the PMA demonstrated 88.1% margin accuracy and a statistically significant reduction in patients with residual cancer post-surgery compared to standard of care alone. Results were presented at the 26th Annual Meeting of the American Society of Breast Surgeons (ASBrS 2025) by Dr. Alastair Thompson, Section Chief of Breast Surgery at Baylor College of Medicine and Primary Principal Investigator of the trial. The data met the threshold for super-superiority, meaning the lower bound of the confidence interval for treatment effect exceeded a predetermined minimal clinically meaningful difference.
The trial was funded in part by a US$7.4 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). Claire's AI was trained on a diverse dataset spanning multiple patient characteristics. A pre-determined change control plan (PCCP) authorized within the PMA approval allows planned AI enhancements to be implemented without additional FDA submissions, giving Perimeter an iterative development pathway post-commercialization.
Platform architecture and competitive moat
Every Claire procedure generates new OCT image data that feeds back into the AI training library, creating a compounding proprietary dataset advantage. This self-reinforcing data loop, built on Perimeter's patented OCT imaging engine, cannot be replicated without the same hardware - effectively locking competitors out of the dataset. Claire is classified as a Class III AI-enabled device, one of a small number of such cleared products on the U.S. market.
Management frames the current breast surgery indication as the first commercialization step on a broader OCT-AI platform targeting additional cancer surgeries, biopsy procedures, and pathology applications. The patented wide-field OCT technology and integrated AI capabilities are designed to scale across indications without rebuilding the underlying imaging infrastructure.
Business impact
Surgical oncology procurement leads and hospital value analysis committees now face a vendor selection decision with a cleared, evidence-backed product in a category that previously had no FDA-approved AI imaging option. The 20% re-operation rate in U.S. breast-conserving surgery translates directly into avoidable facility costs, OR time, and payer claims - giving health system CFOs a measurable ROI argument for adoption. Procurement teams evaluating Claire in 2026 budget cycles must weigh capital device costs against demonstrable reductions in repeat-surgery expenditure and associated liability exposure.
For surgical technology and oncology device distributors, the PMA creates a defined market entry window before competing platforms can complete their own regulatory pathways. Breast surgery program directors and cancer center medical directors will need to update intraoperative margin assessment protocols to account for an FDA-approved AI adjunct, triggering credentialing, training, and workflow integration decisions. The PCCP authorization means Perimeter can improve Claire's AI autonomously, making long-term vendor lock-in a realistic consideration for procurement teams negotiating multi-year contracts.